DMDC

Drug Profile

DMDC

Latest Information Update: 08 May 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Mitsubishi Pharma Corporation; Yamasa Corporation
  • Developer Mitsubishi Pharma Corporation; PPD; Yamasa Corporation
  • Class Antineoplastics; Small molecules
  • Mechanism of Action DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Colorectal cancer; Lung cancer; Non-small cell lung cancer

Most Recent Events

  • 06 Apr 2000 Yoshitomi is now called Welfide Corporation
  • 21 May 1999 PPD Pharmaco is now called PPD Development
  • 11 Jan 1999 Phase-I clinical trials for Non-small cell lung cancer in Poland (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top